On March 23, 2019 in Kyiv a Scientific and Practical conference "Prolongation of survival in patients with a non-small cell pulmonary cancer: when unattainable becomes possible" took place.
The Conference was devoted to registration and introduction of a new preparation for the treatment of a particular molecular biological subtype of pulmonary cancer - osimertynib (trade name Tagrisso) - on pharmaceutical market of Ukraine. Osimertynib belongs to tyrosine kinase inhibitors (TKIs). The preparation is an irreversible inhibitor of epidermal growth factor receptor (EGFR), containing a sensitizing mutation (EGFRm) and a TKI-resistant mutation T790M.
Tagrisso is indicated for the treatment of adult patients with a locally advanced or metastatic non-small cell lung cancer (NSCLC) with the presence of the T790M mutation in the epidermal growth factor receptor (EGFR). The preparation has a high efficiency - higher than in precursors of the same direction action, and, due to a higher level of targeting, - the enhanced patient's safety level.
The Conference was opened by Professor Yuriy Dumanskyi, the Chairman of the National Association of Oncologists of Ukraine. Yuriy Vasylyovych congratulated the participants of the Conference, and stressed the importance of solving of the pulmonary cancer problem in Ukraine and in all over the world. He also emphasized a great significance of introduction of the latest technologies in the field of antitumor therapy.
Dmytro Androsov, the Head of the Oncology Business Unit at Astra Zeneca Ukraine, told about the changes in the modern paradigm of treatment for patients with pulmonary cancer.
The next report by the Head of the Department of Thoracic Tumors of the National Cancer Institute, Yuriy Kondratskyi was devoted to prospects for reduction of mortality from pulmonary cancer in Ukraine due to introduction of new algorithms for diagnosis and therapeutic approaches. A logical continuation of the report by Yuriy Kondratskyi was presentation by Alexander Sukhoversha, devoted to invasive methods for determining of the pulmonary cancer stage and the decision-making algorithm for surgical intervention.
Olena Koschik, a leading pathologist at the CSD Health Care Laboratory, reported on new opportunities for morphological and molecular genetic diagnosis in pulmonary cancer.
The report by Elmira Barder (City of Kharkiv) was devoted to modern approaches for chemotherapeutic treatment of a non-small cell lung cancer.
Yaroslav Shparyk, the Head of the Department of Chemotherapy at the State Cancer Regional Treatment and Diagnostic Center (City of Lviv), made a very impressive and sophisticated report concerning modern approaches to the treatment of a non-small cell lung cancer with EGFR mutation and principal researches, the results of which have changed the therapeutic strategy principally.
The real event at the Conference was a report, made by Global Director of Astra Zenec company on the clinical development of the Tagrisso and Iressa preparations, Yuriy Rukazenkov (Great Britain). So there was presented an in-depth analysis of the results of clinical trials on osimertynib treatment of pulmonary cancer, and it made possible to enlighten the preparation Tagrisso main features and the prospects for the development of a non-small cell lung cancer therapy in patients with EGFR mutation.
Olga Ponomaryova, the Associate Professor of the Oncology Department of Shupyk NMAPE have reported a number of clinical cases with targeted treatment of pulmonary malignancies, using Tagrisso preparation, what have clearly demonstrated the clinical features and benefits of osimertynib application in treatment of a non-small cell lung cancer with EGFR mutation.